Detailed Methodology: Assessing Neutralizing Antibody Responses and DMAb Purification in a Phase 1 Clinical Trial
This document details the methodologies employed in a Phase 1 clinical trial focused on evaluating the safety and immunogenicity of a novel therapeutic. We outline the procedures for assessing neutralizing antibody activity against a pseudovirus, the purification process for domain-matched antibodies (DMAbs) from participant sera, and the statistical approaches used for data analysis. Our goal is to provide a transparent and comprehensive overview of the techniques used to generate robust and reliable findings.
Neutralization Assays: Quantifying viral Inhibition
To determine the ability of participant antibodies to neutralize the virus, we utilized a pseudovirus-based neutralization assay. Serial dilutions of antibody samples were incubated wiht the pseudovirus for 90 minutes at room temperature. This allows for antibody-virus complexes to form before exposure to cells.
Following incubation, the mixture was transferred to human CHO-ACE2 cells – cells engineered to express the human ACE2 receptor, the entry point for the virus. After a 72-hour incubation period, cell viability and viral infection levels were assessed using Britelite Plus, a luminescence-based reporter system. Luminescence intensity directly correlates with the amount of viral infection.
Data analysis was performed using Prism v.10, employing nonlinear regression with a Hill slope of 50 to generate neutralization curves. The reciprocal dilution yielding 50% neutralization (NT50) was calculated. Furthermore, we derived IC50 values by dividing the serum DMAb titer by the ID50, providing a standardized measure of neutralizing potency.
DMAb Purification: Isolating Targeted Antibodies
To specifically isolate and analyze the domain-matched antibodies (DMAbs) responsible for neutralization,we employed a robust purification process. Serum samples (from Day 0 or pooled weeks 24-52) were diluted 1:4 in PBS and incubated overnight at 37°C with anti-YTE-coated Dynabeads. YTE refers to a specific epitope recognized by the antibodies of interest.
These Dynabeads selectively bind to the DMAbs within the serum. Following incubation, the bead complexes were thoroughly washed to remove unbound proteins and then eluted using Pierce IgG Elution Buffer. Two elution fractions were collected to maximize recovery.
For cohorts A1, A2, and D, the eluted DMAbs were concentrated using Amicon 30 kDa MWCO filters. Concentration ensures sufficient material for downstream analysis. The concentration of purified DMAbs was then confirmed using ELISA. This ELISA utilized both anti-YTE capture antibodies and secondary anti-idiotype mAbs (M54-2E9 for AZD5396, M16H5.1 for AZD8076) to specifically quantify the target antibodies. ELISA plates were coated overnight, developed using a standardized protocol, and read on a BioTek Synergy Neo2 reader. Data analysis was performed in Gen5, with graphs generated using Prism v.10.2.1.
Statistical Analysis: A Descriptive Approach
This Phase 1 study was designed primarily for safety assessment and initial characterization of immunogenicity, and was therefore not powered for formal hypothesis testing. Cohort sizes (n=3, 5, or 6) were determined based on pre-specified dose-limiting toxicity (DLT) monitoring parameters, aligning with FDA guidance for first-in-human trials. A DLT threshold of 30% guided cohort expansion or modification.
Smaller sample sizes in the extension phase (cohorts E-G) were dictated by resource constraints, including funding and manufacturing capacity. These exploratory cohorts focused on maximizing scientific data regarding the impact of multisite governance and exposure parameters (EP) on pharmacokinetics (PK) and safety.
Statistical analyses were primarily descriptive. Adverse events (AEs) were tabulated by dose level, system organ class, and preferred term, with frequencies, percentages, and 90% clopper-Pearson confidence intervals (CIs) calculated. Laboratory values,vital signs,and continuous measures were summarized using mean,standard deviation (s.d.), median, and range. PK endpoints,including detection rates and time to 50% decline from peak concentration,were estimated with corresponding CIs. Disposition data (enrollment, dose administration, completion, and discontinuations) were also described. Interim analyses were conducted as needed in response to safety signals, with missing data handled through participant replacement at the investigator’s discretion. All statistical analyses were performed using STATA
Worth a look